Sign in Subscribe
Drugs

Merck Announces Recent Developments in Cancer Vaccine and Targeted Therapy

Strategic Insights

— 2 min read

Merck KGaA, a pharmaceutical company, has recently entered into an agreement with Glenmark Pharmaceuticals for the development and commercialization of Glenmark's DPPIV inhibitor GRC 8200, a treatment for type 2 diabetes. Separately, Merck & Co. announced that the U.S. Food and Drug Administration (FDA) has approved Gardasil, a vaccine that prevents cervical cancer, precancers, and genital warts caused by human papillomavirus (HPV) types 6, 11, 16, and 18. Additionally, Merck has reported positive results from clinical trials of its targeted cancer therapy Erbitux (cetuximab) in combination with irinotecan for the treatment of metastatic colorectal cancer (mCRC).

Key Takeaways:

  • Merck KGaA has entered into an agreement with Glenmark Pharmaceuticals for the development and commercialization of GRC 8200, a DPPIV inhibitor for the treatment of type 2 diabetes, with an expected close date of this year pending approval from U.S. antitrust agencies.
  • Gardasil, a cervical cancer vaccine developed by Merck & Co., has been approved by the FDA for the prevention of cervical cancer, precancers, and genital warts caused by HPV types 6, 11, 16, and 18, with an estimated 4.7 million abnormal Pap results requiring follow-up each year in the United States.
  • Clinical trials of Erbitux (cetuximab) plus irinotecan demonstrated a median survival of 9.2 months in patients with metastatic colorectal cancer (mCRC) who failed prior irinotecan-based treatment, with a progression-free survival rate of 61% at 12 weeks and 34% at 24 weeks.
  • Gardasil has been approved for use in adolescent girls ages 9 to 26, with the FDA citing data from clinical studies showing that the vaccine was generally well-tolerated and effective in preventing HPV-related clinical diseases, including cervical cancer and genital warts.
  • Erbitux, in combination with chemotherapy, has shown a higher response rate compared to chemotherapy alone in previously untreated patients with mCRC, with a significant response rate of 52% versus 38% for chemotherapy alone.
  • Early results from international phase III clinical trials involving over 4,000 patients show that Erbitux trials can continue, with nearly one in four patients with metastatic disease having their previously inoperable metastases removed by surgery.

Statistics:

  • Estimated 4.7 million abnormal Pap results requiring follow-up each year in the United States (Source: CDC).
  • 10,000 women diagnosed with cervical cancer every year in the United States (Source: CDC).
  • 10 women die each day from cervical cancer in the United States (Source: CDC).
  • 1,147 patients participated in a clinical trial of Erbitux plus irinotecan for the treatment of mCRC (Source: Merck).
  • 197 centers in eight European countries participated in the clinical trial of Erbitux plus irinotecan (Source: Merck).
  • 238 patients were enrolled in the CALGB 80203 clinical trial of Erbitux and chemotherapy for the treatment of mCRC (Source: Merck).

Sources:

  • NewsRx.com (report 1: Merck KGaA and Glenmark Pharmaceuticals S.A.).
  • Merck & Co. (report 2: U.S. FDA approval of Gardasil).
  • Health & Medicine Week (report 3: Clinical trial results of Erbitux plus irinotecan for the treatment of mCRC).

Read more